A Phase 1/2, Open-Label Safety and Efficacy Evaluation of CRS-207 in Combination With Epacadostat in Adults With Platinum-Resistant Ovarian, Fallopian, or Peritoneal Cancer

Trial Profile

A Phase 1/2, Open-Label Safety and Efficacy Evaluation of CRS-207 in Combination With Epacadostat in Adults With Platinum-Resistant Ovarian, Fallopian, or Peritoneal Cancer

Discontinued
Phase of Trial: Phase I/II

Latest Information Update: 18 Dec 2017

At a glance

  • Drugs CRS 207 (Primary) ; Epacadostat (Primary) ; Pembrolizumab (Primary)
  • Indications Fallopian tube cancer; Ovarian cancer; Peritoneal cancer
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms SEASCAPE
  • Sponsors Aduro BioTech
  • Most Recent Events

    • 12 Dec 2017 Status changed from active, no longer recruiting to discontinued, according to an Aduro BioTech media release
    • 12 Dec 2017 Status changed from recruiting to active, no longer recruiting.
    • 21 Nov 2016 According to an Aduro BioTech media release, the U.S. Food and Drug Administration (FDA) has lifted the partial clinical hold placed on its clinical trials evaluating the LADD (live, attenuated double-deleted) immunotherapy platform, enabling patient enrollment to resume in all the company-sponsored clinical studies.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top